Geron Corporation (NASDAQ:GERN) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01, Briefing.com reports. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.38 million. Geron Corporation had a negative return on equity of 20.88% and a negative net margin of 433.72%. Geron Corporation’s revenue for the quarter was down 19.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.05) earnings per share.

Geron Corporation (NASDAQ:GERN) traded down 0.48% during mid-day trading on Friday, hitting $2.08. The stock had a trading volume of 1,094,927 shares. The stock’s 50-day moving average price is $2.68 and its 200-day moving average price is $2.47. The stock’s market cap is $331.10 million. Geron Corporation has a 12 month low of $1.81 and a 12 month high of $3.15.

COPYRIGHT VIOLATION WARNING: “Geron Corporation (GERN) Announces Quarterly Earnings Results” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/11/geron-corporation-gern-announces-quarterly-earnings-results.html.

Several analysts have issued reports on the company. FBR & Co reaffirmed a “buy” rating on shares of Geron Corporation in a research note on Tuesday, July 4th. Zacks Investment Research lowered Geron Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, BidaskClub lowered Geron Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $3.88.

Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new position in shares of Geron Corporation during the second quarter worth approximately $114,000. Parametric Portfolio Associates LLC boosted its position in shares of Geron Corporation by 59.4% in the second quarter. Parametric Portfolio Associates LLC now owns 47,976 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 17,877 shares during the period. Tudor Investment Corp ET AL boosted its position in shares of Geron Corporation by 12.1% in the first quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 5,669 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Geron Corporation by 31.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 57,056 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 13,500 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Geron Corporation by 26.5% in the first quarter. Bank of America Corp DE now owns 65,403 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 13,698 shares during the period. 38.16% of the stock is currently owned by institutional investors and hedge funds.

About Geron Corporation

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Earnings History for Geron Corporation (NASDAQ:GERN)

Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with MarketBeat.com's FREE daily email newsletter.